Detalhe da pesquisa
1.
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Int J Cancer
; 150(12): 2072-2082, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179782
2.
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Breast Cancer Res Treat
; 168(1): 17-27, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29128895
3.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Breast Cancer Res Treat
; 166(2): 593-601, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28776283
4.
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.
Acta Oncol
; 56(4): 614-617, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28080180
5.
Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
Br J Cancer
; 114(3): 248-55, 2016 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26742006
6.
Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.
Br J Cancer
; 115(11): 1400-1407, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27701383
7.
Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Breast Cancer Res Treat
; 160(2): 313-322, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27722840
8.
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
JAMA
; 316(18): 1888-1896, 2016 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825007
9.
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Breast Cancer Res Treat
; 153(1): 31-40, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26208487
10.
VAV3 mediates resistance to breast cancer endocrine therapy.
Breast Cancer Res
; 16(3): R53, 2014 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24886537
11.
C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.
Breast Cancer Res Treat
; 145(1): 73-82, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24715380
12.
Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Breast Cancer Res Treat
; 145(1): 61-71, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24715381
13.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Lancet Oncol
; 14(1): 72-80, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23246022
14.
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
Breast Cancer Res
; 15(5): R96, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24131622
15.
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Oncologist
; 18(7): 812-8, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23814044
16.
Placental weight and mortality in premenopausal breast cancer by tumor characteristics.
Breast Cancer Res Treat
; 137(1): 297-305, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23149466
17.
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
Breast Cancer Res Treat
; 137(2): 397-406, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23242584
18.
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.
Breast Cancer Res Treat
; 138(2): 467-73, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23456195
19.
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Breast
; 71: 63-68, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517154
20.
Impact of comorbidity on management and mortality in women diagnosed with breast cancer.
Breast Cancer Res Treat
; 135(1): 281-9, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22829398